title: Improved prognosis of patients presenting with clinical markers of spontaneous reperfusion during acute myocardial infarction.
abstract: OBJECTIVE
  To describe the clinical features, management, and prognosis of patients presenting with clinical markers of spontaneous reperfusion (SR) during acute myocardial infarction (AMI).
  
  
  METHODS
  Cohort study.
  
  
  METHODS
  National registry of 26 coronary care units.
  
  
  METHODS
  2382 consecutive patients with AMI.
  
  
  METHODS
  Patient characteristics, management, and mortality.
  
  
  RESULTS
  The incidence of SR was 4% of patients (n = 98) compared with thrombolytic treatment (n = 1163, 49%), primary angioplasty (n = 102, 4%), and non-reperfusion (n = 1019, 43%). SR patients were more likely to develop less or no myocardial damage as indicated by a higher percentage of non-Q wave AMI (58% v 32%, 47%, and 44%, respectively, p < 0.0001), aborted AMI (25% v 9%, 8%, and 12%, p < 0.001), and lower peak creatine kinase (503 v 1384, 1519, and 751 IU, p < 0.0001). SR patients, however, were more likely to develop recurrent ischaemic events (35% v 17%, 12%, and 16%, respectively; p < 0.001) and subsequently were more likely to be referred to coronary angiography (67%), angioplasty (41%), or bypass surgery (16%, p < 0.001). Mortality at 30 days (1% v 8%, 7%, and 13%, respectively, p < 0.0001) and one year (6% v 11%, 12%, and 19%, p < 0.0001) was significantly lower for SR patients than for the other subgroups. By multivariate analysis, SR remained a strong determinant of 30 day survival (odds ratio (OR) 0.16, 95% confidence interval (CI) 0.01 to 0.74). At one year, the association between SR and survival decreased (OR 0.49, 95% CI 0.18 to 1.13).
  
  
  CONCLUSIONS
  Clinical markers of SR are associated with greater myocardial salvage and favourable prognosis. The vulnerability of SR patients to recurrent ischaemic events suggests that they need close surveillance and may benefit from early intervention.
authors.affiliation: Cardiology Department, Soroka Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
authors.forename: D
authors.initials: D
authors.lastname: Rimar
authors.forename: E
authors.initials: E
authors.lastname: Crystal
authors.forename: A
authors.initials: A
authors.lastname: Battler
authors.forename: S
authors.initials: S
authors.lastname: Gottlieb
authors.forename: D
authors.initials: D
authors.lastname: Freimark
authors.forename: H
authors.initials: H
authors.lastname: Hod
authors.forename: V
authors.initials: V
authors.lastname: Boyko
authors.forename: L
authors.initials: L
authors.lastname: Mandelzweig
authors.forename: S
authors.initials: S
authors.lastname: Behar
authors.forename: J
authors.initials: J
authors.lastname: Leor
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D005260:Female; D017052:Hospital Mortality; D006760:Hospitalization; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000401:mortality / Q000628:therapy*; D015425:Myocardial Reperfusion; D011379:Prognosis; D011446:Prospective Studies; D015912:Thrombolytic Therapy / Q000379:methods
chemical_list: D015415:Biomarkers